Is it All Said for NSAIDs in Alzheimer's Disease? Role of Mitochondrial Calcium Uptake
- Autores
- Sanz Blasco, Sara Isabel; Calvo Rodriguez, Maria; Caballero, Erica; Garcia-Durillo, Monica; Nunez, Lucia; Villalobos, Carlos
- Año de publicación
- 2018
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Epidemiological data suggest that non-steroidal anti-inflammatory drugs (NSAIDs) may protect against Alzheimer´s disease (AD). Unfortunately, recent trials have failed in providing compelling evidence of neuroprotection. Discussion as to why NSAIDs effectivity is uncertain is ongoing. Possible explanations include the view that NSAIDs and other possible disease-modifying drugs should be provided before the patients develop symptoms of AD or cognitive decline. In addition, NSAID targets for neuroprotection are unclear. Both COX-dependent and independent mechanisms have been proposed, including γ-secretase that cleaves the amyloid precursor protein (APP) and yields amyloid β peptide (Aβ). We have proposed a neuroprotection mechanism for NSAIDs based on inhibition of mitochondrial Ca2+ overload. Aβ oligomers promote Ca2+ influx and mitochondrial Ca2+ overload leading to neuron cell death. Several non-specific NSAIDs including ibuprofen, sulindac, indomethacin and R-flurbiprofen depolarize mitochondria in the low µM range and prevent mitochondrial Ca2+ overload induced by Aβ oligomers and/or N-methyl-D-aspartate (NMDA). However, at larger concentrations, NSAIDs may collapse mitochondrial potential (ΔΨ) leading to cell death. Accordingly, this mechanism may explain neuroprotection at low concentrations and damage at larger doses, thus providing clues on the failure of promising trials. Perhaps lower NSAID concentrations and/or alternative compounds with larger dynamic ranges should be considered for future trials to provide definitive evidence of neuroprotection against AD.
Fil: Sanz Blasco, Sara Isabel. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Consejo Superior de Investigaciones Científicas; España
Fil: Calvo Rodriguez, Maria. Consejo Superior de Investigaciones Científicas; España
Fil: Caballero, Erica. Consejo Superior de Investigaciones Científicas; España
Fil: Garcia-Durillo, Monica. Consejo Superior de Investigaciones Científicas; España
Fil: Nunez, Lucia. Consejo Superior de Investigaciones Científicas; España
Fil: Villalobos, Carlos. Consejo Superior de Investigaciones Científicas; España - Materia
-
Alzheimer'S Disease
Non-Steroidal Anti-Inflammatory Drugs
Calcium
Mitochondria
Amyloid Β Oligomers
N-Methyl-D-Aspartate - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/47161
Ver los metadatos del registro completo
id |
CONICETDig_3505372a50c07b967b9de525967ea9ce |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/47161 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Is it All Said for NSAIDs in Alzheimer's Disease? Role of Mitochondrial Calcium UptakeSanz Blasco, Sara IsabelCalvo Rodriguez, MariaCaballero, EricaGarcia-Durillo, MonicaNunez, LuciaVillalobos, CarlosAlzheimer'S DiseaseNon-Steroidal Anti-Inflammatory DrugsCalciumMitochondriaAmyloid Β OligomersN-Methyl-D-Aspartatehttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3Epidemiological data suggest that non-steroidal anti-inflammatory drugs (NSAIDs) may protect against Alzheimer´s disease (AD). Unfortunately, recent trials have failed in providing compelling evidence of neuroprotection. Discussion as to why NSAIDs effectivity is uncertain is ongoing. Possible explanations include the view that NSAIDs and other possible disease-modifying drugs should be provided before the patients develop symptoms of AD or cognitive decline. In addition, NSAID targets for neuroprotection are unclear. Both COX-dependent and independent mechanisms have been proposed, including γ-secretase that cleaves the amyloid precursor protein (APP) and yields amyloid β peptide (Aβ). We have proposed a neuroprotection mechanism for NSAIDs based on inhibition of mitochondrial Ca2+ overload. Aβ oligomers promote Ca2+ influx and mitochondrial Ca2+ overload leading to neuron cell death. Several non-specific NSAIDs including ibuprofen, sulindac, indomethacin and R-flurbiprofen depolarize mitochondria in the low µM range and prevent mitochondrial Ca2+ overload induced by Aβ oligomers and/or N-methyl-D-aspartate (NMDA). However, at larger concentrations, NSAIDs may collapse mitochondrial potential (ΔΨ) leading to cell death. Accordingly, this mechanism may explain neuroprotection at low concentrations and damage at larger doses, thus providing clues on the failure of promising trials. Perhaps lower NSAID concentrations and/or alternative compounds with larger dynamic ranges should be considered for future trials to provide definitive evidence of neuroprotection against AD.Fil: Sanz Blasco, Sara Isabel. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Consejo Superior de Investigaciones Científicas; EspañaFil: Calvo Rodriguez, Maria. Consejo Superior de Investigaciones Científicas; EspañaFil: Caballero, Erica. Consejo Superior de Investigaciones Científicas; EspañaFil: Garcia-Durillo, Monica. Consejo Superior de Investigaciones Científicas; EspañaFil: Nunez, Lucia. Consejo Superior de Investigaciones Científicas; EspañaFil: Villalobos, Carlos. Consejo Superior de Investigaciones Científicas; EspañaBentham Science Publishers2018-04info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/47161Sanz Blasco, Sara Isabel; Calvo Rodriguez, Maria; Caballero, Erica; Garcia-Durillo, Monica; Nunez, Lucia; et al.; Is it All Said for NSAIDs in Alzheimer's Disease? Role of Mitochondrial Calcium Uptake; Bentham Science Publishers; Current Alzheimer Research; 15; 6; 4-2018; 504-5101567-2050CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.2174/1567205015666171227154016info:eu-repo/semantics/altIdentifier/url/http://www.eurekaselect.com/158662/articleinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-15T14:39:41Zoai:ri.conicet.gov.ar:11336/47161instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-15 14:39:41.926CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Is it All Said for NSAIDs in Alzheimer's Disease? Role of Mitochondrial Calcium Uptake |
title |
Is it All Said for NSAIDs in Alzheimer's Disease? Role of Mitochondrial Calcium Uptake |
spellingShingle |
Is it All Said for NSAIDs in Alzheimer's Disease? Role of Mitochondrial Calcium Uptake Sanz Blasco, Sara Isabel Alzheimer'S Disease Non-Steroidal Anti-Inflammatory Drugs Calcium Mitochondria Amyloid Β Oligomers N-Methyl-D-Aspartate |
title_short |
Is it All Said for NSAIDs in Alzheimer's Disease? Role of Mitochondrial Calcium Uptake |
title_full |
Is it All Said for NSAIDs in Alzheimer's Disease? Role of Mitochondrial Calcium Uptake |
title_fullStr |
Is it All Said for NSAIDs in Alzheimer's Disease? Role of Mitochondrial Calcium Uptake |
title_full_unstemmed |
Is it All Said for NSAIDs in Alzheimer's Disease? Role of Mitochondrial Calcium Uptake |
title_sort |
Is it All Said for NSAIDs in Alzheimer's Disease? Role of Mitochondrial Calcium Uptake |
dc.creator.none.fl_str_mv |
Sanz Blasco, Sara Isabel Calvo Rodriguez, Maria Caballero, Erica Garcia-Durillo, Monica Nunez, Lucia Villalobos, Carlos |
author |
Sanz Blasco, Sara Isabel |
author_facet |
Sanz Blasco, Sara Isabel Calvo Rodriguez, Maria Caballero, Erica Garcia-Durillo, Monica Nunez, Lucia Villalobos, Carlos |
author_role |
author |
author2 |
Calvo Rodriguez, Maria Caballero, Erica Garcia-Durillo, Monica Nunez, Lucia Villalobos, Carlos |
author2_role |
author author author author author |
dc.subject.none.fl_str_mv |
Alzheimer'S Disease Non-Steroidal Anti-Inflammatory Drugs Calcium Mitochondria Amyloid Β Oligomers N-Methyl-D-Aspartate |
topic |
Alzheimer'S Disease Non-Steroidal Anti-Inflammatory Drugs Calcium Mitochondria Amyloid Β Oligomers N-Methyl-D-Aspartate |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.1 https://purl.org/becyt/ford/3 |
dc.description.none.fl_txt_mv |
Epidemiological data suggest that non-steroidal anti-inflammatory drugs (NSAIDs) may protect against Alzheimer´s disease (AD). Unfortunately, recent trials have failed in providing compelling evidence of neuroprotection. Discussion as to why NSAIDs effectivity is uncertain is ongoing. Possible explanations include the view that NSAIDs and other possible disease-modifying drugs should be provided before the patients develop symptoms of AD or cognitive decline. In addition, NSAID targets for neuroprotection are unclear. Both COX-dependent and independent mechanisms have been proposed, including γ-secretase that cleaves the amyloid precursor protein (APP) and yields amyloid β peptide (Aβ). We have proposed a neuroprotection mechanism for NSAIDs based on inhibition of mitochondrial Ca2+ overload. Aβ oligomers promote Ca2+ influx and mitochondrial Ca2+ overload leading to neuron cell death. Several non-specific NSAIDs including ibuprofen, sulindac, indomethacin and R-flurbiprofen depolarize mitochondria in the low µM range and prevent mitochondrial Ca2+ overload induced by Aβ oligomers and/or N-methyl-D-aspartate (NMDA). However, at larger concentrations, NSAIDs may collapse mitochondrial potential (ΔΨ) leading to cell death. Accordingly, this mechanism may explain neuroprotection at low concentrations and damage at larger doses, thus providing clues on the failure of promising trials. Perhaps lower NSAID concentrations and/or alternative compounds with larger dynamic ranges should be considered for future trials to provide definitive evidence of neuroprotection against AD. Fil: Sanz Blasco, Sara Isabel. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Consejo Superior de Investigaciones Científicas; España Fil: Calvo Rodriguez, Maria. Consejo Superior de Investigaciones Científicas; España Fil: Caballero, Erica. Consejo Superior de Investigaciones Científicas; España Fil: Garcia-Durillo, Monica. Consejo Superior de Investigaciones Científicas; España Fil: Nunez, Lucia. Consejo Superior de Investigaciones Científicas; España Fil: Villalobos, Carlos. Consejo Superior de Investigaciones Científicas; España |
description |
Epidemiological data suggest that non-steroidal anti-inflammatory drugs (NSAIDs) may protect against Alzheimer´s disease (AD). Unfortunately, recent trials have failed in providing compelling evidence of neuroprotection. Discussion as to why NSAIDs effectivity is uncertain is ongoing. Possible explanations include the view that NSAIDs and other possible disease-modifying drugs should be provided before the patients develop symptoms of AD or cognitive decline. In addition, NSAID targets for neuroprotection are unclear. Both COX-dependent and independent mechanisms have been proposed, including γ-secretase that cleaves the amyloid precursor protein (APP) and yields amyloid β peptide (Aβ). We have proposed a neuroprotection mechanism for NSAIDs based on inhibition of mitochondrial Ca2+ overload. Aβ oligomers promote Ca2+ influx and mitochondrial Ca2+ overload leading to neuron cell death. Several non-specific NSAIDs including ibuprofen, sulindac, indomethacin and R-flurbiprofen depolarize mitochondria in the low µM range and prevent mitochondrial Ca2+ overload induced by Aβ oligomers and/or N-methyl-D-aspartate (NMDA). However, at larger concentrations, NSAIDs may collapse mitochondrial potential (ΔΨ) leading to cell death. Accordingly, this mechanism may explain neuroprotection at low concentrations and damage at larger doses, thus providing clues on the failure of promising trials. Perhaps lower NSAID concentrations and/or alternative compounds with larger dynamic ranges should be considered for future trials to provide definitive evidence of neuroprotection against AD. |
publishDate |
2018 |
dc.date.none.fl_str_mv |
2018-04 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/47161 Sanz Blasco, Sara Isabel; Calvo Rodriguez, Maria; Caballero, Erica; Garcia-Durillo, Monica; Nunez, Lucia; et al.; Is it All Said for NSAIDs in Alzheimer's Disease? Role of Mitochondrial Calcium Uptake; Bentham Science Publishers; Current Alzheimer Research; 15; 6; 4-2018; 504-510 1567-2050 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/47161 |
identifier_str_mv |
Sanz Blasco, Sara Isabel; Calvo Rodriguez, Maria; Caballero, Erica; Garcia-Durillo, Monica; Nunez, Lucia; et al.; Is it All Said for NSAIDs in Alzheimer's Disease? Role of Mitochondrial Calcium Uptake; Bentham Science Publishers; Current Alzheimer Research; 15; 6; 4-2018; 504-510 1567-2050 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/doi/10.2174/1567205015666171227154016 info:eu-repo/semantics/altIdentifier/url/http://www.eurekaselect.com/158662/article |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Bentham Science Publishers |
publisher.none.fl_str_mv |
Bentham Science Publishers |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1846082884067131392 |
score |
13.22299 |